Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares gapped up prior to trading on Friday . The stock had previously closed at $14.33, but opened at $14.81. Aclaris Therapeutics shares last traded at $14.85, with a volume of 333,935 shares traded.
Analyst Ratings Changes
Several research firms have recently issued reports on ACRS. StockNews.com began coverage on Aclaris Therapeutics in a research report on Wednesday, October 12th. They issued a "sell" rating for the company. SVB Leerink reissued an "outperform" rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. Stifel Nicolaus started coverage on Aclaris Therapeutics in a research report on Tuesday, December 13th. They issued a "buy" rating and a $29.00 target price for the company. Finally, The Goldman Sachs Group initiated coverage on Aclaris Therapeutics in a research report on Thursday, December 1st. They issued a "buy" rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.67.
Get Aclaris Therapeutics alerts:Aclaris Therapeutics Stock Performance
The company has a fifty day moving average of $16.04 and a two-hundred day moving average of $16.07. The company has a market cap of $936.90 million, a PE ratio of -10.89 and a beta of 0.57.
Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last released its earnings results on Tuesday, November 8th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.09. Aclaris Therapeutics had a negative return on equity of 39.41% and a negative net margin of 349.26%. The business had revenue of $19.02 million for the quarter, compared to analyst estimates of $1.61 million. On average, equities analysts forecast that Aclaris Therapeutics, Inc. will post -1.39 EPS for the current year.Insider Transactions at Aclaris Therapeutics
In related news, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total transaction of $381,250.00. Following the completion of the transaction, the director now directly owns 1,220,763 shares in the company, valued at $18,616,635.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total value of $79,400.00. Following the sale, the insider now directly owns 96,386 shares of the company's stock, valued at $1,530,609.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total value of $381,250.00. Following the completion of the sale, the director now directly owns 1,220,763 shares in the company, valued at $18,616,635.75. The disclosure for this sale can be found here. Company insiders own 6.70% of the company's stock.
Hedge Funds Weigh In On Aclaris Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACRS. Wellington Management Group LLP raised its position in Aclaris Therapeutics by 3.4% in the first quarter. Wellington Management Group LLP now owns 5,730,253 shares of the biotechnology company's stock valued at $98,789,000 after purchasing an additional 190,985 shares during the period. BlackRock Inc. increased its holdings in Aclaris Therapeutics by 3.0% during the 3rd quarter. BlackRock Inc. now owns 4,810,298 shares of the biotechnology company's stock worth $75,714,000 after purchasing an additional 140,382 shares during the period. Vanguard Group Inc. boosted its position in shares of Aclaris Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,931,709 shares of the biotechnology company's stock worth $46,145,000 after acquiring an additional 118,024 shares in the last quarter. Commodore Capital LP boosted its position in shares of Aclaris Therapeutics by 4.1% during the 2nd quarter. Commodore Capital LP now owns 2,410,622 shares of the biotechnology company's stock worth $33,652,000 after acquiring an additional 95,974 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Aclaris Therapeutics by 6.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,853,251 shares of the biotechnology company's stock worth $29,170,000 after acquiring an additional 119,351 shares in the last quarter. Institutional investors and hedge funds own 95.33% of the company's stock.
Aclaris Therapeutics Company Profile
(Get Rating)
Aclaris Therapeutics, Inc operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments.
Featured Articles
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.